| 9.29 0.24 (2.65%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 11.98 | 1-year : | 13.99 |
| Resists | First : | 10.26 | Second : | 11.98 |
| Pivot price | 8.31 |
|||
| Supports | First : | 7.13 | Second : | 5.21 |
| MAs | MA(5) : | 9.02 |
MA(20) : | 7.72 |
| MA(100) : | 9.36 |
MA(250) : | 6.54 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 73 |
D(3) : | 72 |
| RSI | RSI(14): 60.7 |
|||
| 52-week | High : | 15.05 | Low : | 1.8 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ SLDB ] has closed below upper band by 23.1%. Bollinger Bands are 5.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.65 - 9.69 | 9.69 - 9.72 |
| Low: | 9.03 - 9.07 | 9.07 - 9.11 |
| Close: | 9.22 - 9.29 | 9.29 - 9.35 |
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Fri, 26 Jul 2024
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth - Simply Wall St
Mon, 15 Jul 2024
Solid Biosciences up 10% following J.P. Morgan upgrade (NASDAQ:SLDB - Seeking Alpha
Mon, 15 Jul 2024
Solid Biosciences (NASDAQ:SLDB) Upgraded at JPMorgan Chase & Co. - Defense World
Mon, 15 Jul 2024
JPMorgan upgrades Solid Biosciences stock, sees growth potential - Investing.com
Sat, 13 Jul 2024
Short Interest in Solid Biosciences Inc. (NASDAQ:SLDB) Expands By 237.4% - MarketBeat
Mon, 01 Jul 2024
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 94.5 (%) |
| Shares Short | 3,050 (K) |
| Shares Short P.Month | 840 (K) |
| EPS | -3.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.57 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -45.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -63 (M) |
| PE Ratio | -2.37 |
| PEG Ratio | 0 |
| Price to Book value | 1.66 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|